Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women
PHASE1CompletedINTERVENTIONAL
Enrollment
16
Participants
Timeline
Start Date
March 8, 2016
Primary Completion Date
May 31, 2018
Study Completion Date
May 31, 2018
Conditions
HIV Prevention
Interventions
DRUG
Tenofovir Disoproxil Fumarate/Emtricitabine
Trial Locations (1)
21287
Johns Hopkins University Drug Development Unit, Baltimore
All Listed Sponsors
lead
Johns Hopkins University
OTHER
NCT03060785 - Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women | Biotech Hunter | Biotech Hunter